MRNA
Moderna Pharmaceuticals (NASDAQ: MRNA) rose over 28% this week after an FDA advisory committee voted...
Article Summary
BUY- Moderna Pharmaceuticals (NASDAQ: MRNA) rose over 28% this week after an FDA advisory committee voted unanimously in favor of its mRNA seasonal flu vaccine for older adults, marking its best week since March 2022.
- The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of mRNA-1010, also known as mFLUSIVA, outweigh its risks for adults aged 50-64, with the panel also voting 9-1 in favor for the vaccine for people aged 65 or above during its June 18 meeting.
- The FDA is now considering the non-binding recommendations as part of its review of Moderna's Biologics License Application and is slated to decide on the application by August 5.
- Jefferies reiterated a 'Hold' rating and $45 price target, noting FDA decisions align with advisory committee recommendations 84% of the time between 2020 and 2025, with analysts expecting $750 million in combined U.S. flu and flu/covid combo sales by 2030.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -30.0% | 25% | 0.0 ptsDeclining (-30.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 26.3% | 25% | 80.0 ptsVery Good (26.3%) - Good outlook |
| Target Price Upside ? | 26.7% above | 20% | 0.0 ptsAbove Target (26.7% above) - Target: $46.90 vs Current: $63.96 |
| Gross Margin % ? | 11.6% | 15% | 20.0 ptsThin (11.6%) - Low-margin business |
| Drawdown from 52-Wk High ? | 2.7% | 15% | 20.0 ptsBarely a Dip (2.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MRNA
- Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
- The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
- It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
- It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
- The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
- Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.